Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation

Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, USA.
Journal of Medicinal Chemistry (Impact Factor: 5.48). 06/2005; 48(10):3474-7. DOI: 10.1021/jm050069n
Source: PubMed

ABSTRACT Herein we describe a novel series of compounds from which varenicline (1, 6,7,8,9-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine) has been identified for smoking cessation. Neuronal nicotinic acetylcholine receptors (nAChRs) mediate the dependence-producing effects of nicotine. We have pursued alpha4beta2 nicotinic receptor partial agonists to inhibit dopaminergic activation produced by smoking while simultaneously providing relief from the craving and withdrawal syndrome that accompanies cessation attempts. Varenicline displays high alpha4beta2 nAChR affinity and the desired in vivo dopaminergic profile.

Download full-text


Available from: Michael G. Vetelino, Oct 09, 2014
  • Source
    • "Varenicline, in addition to its known partial agonist activity at a4b2 nAChRs (Coe et al., 2005; Rollema et al., 2007), has recently been shown to posses high affinity for and partial agonist activity at a6 ⁄ nAChRs in the DA system. Using agonist-evoked DA release from mouse striatal synaptosomes, Grady and colleagues measured varenicline-induced release at aCtxMIIresistant (a4b2 and a4a5b2 nAChRs) and aCtxMIIsensitive (a4a6b2b3, a4a6b2, a6b2b3, and a6b2 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Acetylcholine acts through nicotinic and muscarinic acetylcholine (ACh) receptors in ventral midbrain and striatal areas to influence dopamine (DA) transmission. This cholinergic control of DA transmission is important for processes such as attention and motivated behavior, and is manipulated by nicotine in tobacco products. Identifying and characterizing the key ACh receptors involved in cholinergic control of DA transmission could lead to small molecule therapeutics for treating disorders involving attention, addiction, Parkinson's disease, and schizophrenia. α6-containing nicotinic acetylcholine receptors (nAChRs) are highly and specifically expressed in midbrain DA neurons, making them an attractive drug target. Here, we used genetic, pharmacological, behavioral, and biophysical approaches to study this nAChR subtype. For many experiments, we used mice expressing mutant α6 nAChRs ("α6L9S" mice) that increase the sensitivity of these receptors to agonists such as ACh and nicotine. Taking advantage of a simple behavioral phenotype exhibited by α6L9S mice, we compared the ability of full versus partial α6∗ nAChR agonists to activate α6∗ nAChRs in vivo. Using local infusions of both agonists and antagonists into brain, we demonstrate that neurons and nAChRs in the midbrain are sufficient to account for this behavioral response. To complement these behavioral studies, we studied the ability of in vivo α6∗ nAChR activation to support plasticity changes in midbrain DA neurons that are relevant to behavioral sensitization and addiction. By coupling local infusion of drugs and brain slice patch clamp electrophysiology, we show that activating α6∗ nAChRs in midbrain DA areas is sufficient to enhance glutamatergic transmission in VTA DA neurons. Together, these results from in vivo studies strongly suggest that α6∗ nAChRs expressed by VTA DA neurons are positioned to strongly influence both DA-mediated behaviors and the induction of synaptic plasticity by nicotine. Copyright © 2015. Published by Elsevier Ltd.
    Neuroscience 07/2015; DOI:10.1016/j.neuroscience.2015.07.052 · 3.33 Impact Factor
  • Source
    • "cessation. It is a partial agonist of a4b2 nicotinic acetylcholine receptors (nAChRs), and a full agonist of a7 nAChR [4] [5]. Varenicline is more effective than nicotine replacement therapy and frequently used clinically for smoking cessation [6] [7] [8]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Varenicline is one of the most widely used drugs for smoking cessation. However, whether an adverse effect of varenicline is associated with the risk of serious cardiovascular events remains controversial. In this study, we determined if varenicline increases the risk of cardiovascular events using apolipoprotein E knockout (ApoE KO) mice. ApoE KO mice (8 weeks old) were injected with varenicline 0.5 mg kg(-1) day(-1) for 3 weeks. Varenicline aggravated atherosclerotic plaque formation in whole aorta from ApoE KO mice compared with vehicle. Methyllycaconitine, an alpha 7 nicotinic acetylcholine receptor (nAChR) antagonist, inhibited varenicline-induced aggravated plaque formation. Our findings show that varenicline progresses atherosclerotic plaque formation through alpha 7 nAChR, and thereby increases the risk of cardiovascular events. (C) 2014 The Authors. Published by Elsevier Inc.
    Biochemical and Biophysical Research Communications 11/2014; 455(3-4). DOI:10.1016/j.bbrc.2014.10.150 · 2.28 Impact Factor
  • Source
    • "In accordance, in the present study, we aimed to explore the contribution of α 4 β 2 receptors on non-invasive brain stimulation-induced focal and non-focal plasticity in human non-smokers via application of varenicline. Varenicline is an effective smoking cessation agent (Coe et al. 2005), which is a high-affinity partial agonist to α 4 β 2 and full agonist to α 7 nAChRs (Mihalak et al. 2006). Varenicline is also suggested to have therapeutic effects in patients suffering from Alzheimer's disease (Kem 2000; Jensen et al. 2005), schizophrenia, depression during smoking abstinence (Hong et al. 2011; Liu et al. 2011; Shim et al. 2012; Anthenelli et al. 2013), and patients with ataxia (Zesiewicz et al. 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nicotine alters cognitive functions in animals and humans most likely by modification of brain plasticity. In the human brain, it alters plasticity induced by transcranial direct current stimulation (tDCS) and paired associative stimulation (PAS), probably by interference with calcium-dependent modulation of the glutamatergic system. We aimed to test this hypothesis further by exploring the impact of the α4β2-nicotinic receptor partial agonist varenicline on focal and non-focal plasticity, induced by PAS and tDCS, respectively. We administered low (0.1 mg), medium (0.3 mg), and high (1.0 mg) single doses of varenicline or placebo medication before PAS or tDCS on the left motor cortex of 25 healthy non-smokers. Corticospinal excitability was monitored by single-pulse transcranial magnetic stimulation-induced motor evoked potential amplitudes up to 36 h after plasticity induction. Whereas low-dose varenicline had no impact on stimulation-induced neuroplasticity, medium-dose abolished tDCS-induced facilitatory after-effects, favoring focal excitatory plasticity. High-dose application preserved cathodal tDCS-induced excitability diminution and focal excitatory PAS-induced facilitatory plasticity. These results are comparable to the impact of nicotine receptor activation and might help to further explain the involvement of specific receptor subtypes in the nicotinic impact on neuroplasticity and cognitive functions in healthy subjects and patients with neuropsychiatric diseases.
    Cerebral Cortex 06/2014; 25(9). DOI:10.1093/cercor/bhu126 · 8.67 Impact Factor
Show more